PRECISION THERAPEUTICS FOR ACUTE ISCHEMIC INJURY

Let’s work together to preserve tissue.

We are developing long half-life HGF mimetics designed to preserve tissue during ischemia reperfusion injury. We welcome discussions with investors, strategic partners, clinicians and researchers.

SEND US A MESSAGE

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

We typically reply within two days

PARTNER WITH WAVENTRA

Seeking collaborations and partnerships in

STEMI and acute coronary syndrome

Hemorrhagic shock and trauma

Ischemic stroke and CNS injury

CMC, manufacturing and clinical development

INVESTMENT OPPORTUNITIES

WAV-301 preclinical development for STEMI

Upcoming milestones

Rat MI studies

Pig MI studies

IND enabling development

Request investor materials

MEDIA AND SCIENTIFIC INQUIRIES

Questions regarding:

HGF biology

Ischemia reperfusion injury

WAV-301, WAV-401

Wavefront AI platform

Info@waventratx.com

OUR ADDRESS

Waventra Therapeutics 2450 Holcombe Blvd Houston, TX 77021

TMC Innovation Factory Texas Medical Center

Located in the heart of the Texas Medical Center, the world’s largest medical complex and innovation ecosystem.

MEET THE FOUNDERS

Waventra Therapeutics was founded by a team of seasoned biotech entrepreneurs with deep expertise in drug discovery, clinical development and company building. We are committed to advancing a differentiated platform to address one of the most urgent challenges in medicine. You can reach Jim Kelly at jkelly@waventratx.com or David Huizenga at dhuizenga@waventratx.com

Together, we can restore what matters

Early targeted intervention can preserve what matters most

EXPLORE THE PIPELINE